| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0889-857X(05)70211-8 |
| P698 | PubMed publication ID | 11396102 |
| P2093 | author name string | Keystone EC | |
| P2860 | cites work | Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis | Q24564656 |
| Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis | Q28239197 | ||
| A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate | Q28295474 | ||
| PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases | Q33782360 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis | Q35132863 | ||
| Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo | Q37031936 | ||
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis | Q37253521 | ||
| The biology of cachectin/TNF--a primary mediator of the host response | Q38269386 | ||
| Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group | Q41924053 | ||
| Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications | Q41930813 | ||
| Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis | Q42694138 | ||
| Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis | Q44064388 | ||
| Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis | Q47849220 | ||
| Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. | Q48851709 | ||
| Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. | Q52221782 | ||
| Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α | Q56813295 | ||
| Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis | Q60461810 | ||
| Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis | Q68028260 | ||
| Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis | Q71160288 | ||
| Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy | Q73117771 | ||
| Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis | Q73374703 | ||
| Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis | Q73374754 | ||
| Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein | Q73502940 | ||
| Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis | Q73573994 | ||
| Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis | Q77341367 | ||
| Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy | Q77430909 | ||
| Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2) | Q77742355 | ||
| P433 | issue | 2 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 427-443 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | Rheumatic Diseases Clinics of North America | Q7320483 |
| P1476 | title | Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis | |
| P478 | volume | 27 |
| Q37814549 | A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. |
| Q35111841 | Abandoned therapies and unpublished trials in rheumatoid arthritis |
| Q47623264 | Abatacept and granulocyte-colony stimulating factor in a patient with rheumatoid arthritis and neutropenia. |
| Q79358241 | Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor |
| Q41120913 | Biologics in dermatology: adverse effects |
| Q38661263 | Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy |
| Q33708863 | Does safety make a difference in selecting the right TNF antagonist? |
| Q35902661 | From laboratory to clinic: rationale for biologic therapy |
| Q35760039 | High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis |
| Q41866942 | Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines |
| Q28202653 | Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis |
| Q44366629 | N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors |
| Q34990105 | New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies |
| Q43886256 | Pyridazine based inhibitors of p38 MAPK. |
| Q80167853 | Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy |
| Q33401933 | Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy |
| Q35597974 | Rheumatoid arthritis. Targeted interventions can minimize joint destruction |
| Q80080214 | Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis |
| Q35176348 | The TNF receptor superfamily: role in immune inflammation and bone formation |
| Q39956024 | Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides |
| Q38087506 | Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans |
Search more.